Are tumoral factors responsible for host tissue wasting in cancer cachexia?

Papers of special note have been highlighted as: ▪ of interest ▪▪ of considerable interest

Bibliography

• 1  Teunissen SC, Wesker W, Kruilwagen C et al.: Symptom prevalence in patients with incurable cancer: a systematic review. J. Pain Symptom Manage.34,94–104 (2007).
  MedlineGoogle Scholar
• 2  Tan BHL, Fearon KCH: Cachexia: prevalence and impact in medicine. Curr. Opin. Clin. Nutr. Metab. Care11,400–407 (2008).
  MedlineGoogle Scholar
• 3  DeWys WD, Begg C, Lavin PT et al.: Prognostic effect of weight loss prior to chemotherapy in cancer patients. Am. J. Med.69,491–497 (1980).
  Medline CASGoogle Scholar
• 4  Marinoho LA, Rettori O, Vieira-Matos AN: Body weight loss as an indicator of breast cancer recurrence. Acta Oncologica40,832–837 (2001).
  MedlineGoogle Scholar
• 5  Cohn SA, Gartenhaus W, Sawitsky A et al.: Compartmental body composition of cancer patients with measurement of total body nitrogen, potassium and water. Metabolism30,222–229 (1981).
  Medline CASGoogle Scholar
• 6  Fearon KCH: The mechanisms and treatment of weight loss in cancer. Proc. Nutr. Soc.51,251–265 (1992).
  Medline CASGoogle Scholar
• 7  Heymsfield SB, McManus CB: Tissue components of weight loss in cancer patients. Cancer55,2238–2242 (1985).
  Google Scholar
• 8  Evans WK, Makuch R, Clamon GH et al.: Limited impact of total parenteral nutrition on nutrition status during treatment for small cell lung cancer. Cancer Res.45,3347–3352 (1985).
  Medline CASGoogle Scholar
• 9  Loprinzi CL, Schaid DJ, Dose AM, Burnham NL, Jensen MD: Body composition changes in patients who gain weight while receiving megestrol acetate. J. Clin. Oncol.11,152–154 (1993).
  Medline CASGoogle Scholar
• 10  Simons JP, Schols AM, Hoefnagels JM, Westerterp KR, ten Velde GP, Wouters EF: Effects of medroxyprogesterone acetate on food intake, body composition and resting energy expenditure in patients with advanced, non-hormone-sensitive cancer. Cancer82,553–560 (1998).
  Medline CASGoogle Scholar
• 11  Bosneus I, Daneryd P, Svanberg E, Lundholm K: Dietary intake and resting energy expenditure in relation to weight loss in unselected cancer patients. Int. J. Cancer93,380–383 (2001).▪▪ Study of 297 cancer patients that demonstrated that weight loss could not be accounted for by diminished dietary intake, since energy intake in absolute amounts was not reduced.
  MedlineGoogle Scholar
• 12  Bing C, Brown M, King P, Collins P, Tisdale MJ, Williams G: Increased gene expression of brown fat uncoupling protein (UCP)1 and skeletal muscle UCP2 and UCP3 in MAC16-induced cancer cachexia. Cancer Res.60,2405–2410 (2000).▪ Comprehensive review of cancer cachexia.
  Medline CASGoogle Scholar
• 13  Fan W, Boston BA, Keterson RA, Hruby VJ, Cone RD: Role of melanocortinergic neurons in feeding and the agouti obesity syndrome. Nature365,165–168 (1997).
  Google Scholar
• 14  Wisse BE, Frayo RS, Schwartz MW, Cumings DE: Reversal of cancer anorexia by blockage of central melanocortin receptors in rats. Endocrinology14,3292–3301 (2001).
  Google Scholar
• 15  Marks DL, Ling N, Cone RD: Role of central melanocortin system in cachexia. Cancer Res.61,1432–1438 (2001).
  Medline CASGoogle Scholar
• 16  Billingsley KG, Fraker DL, Strassman G, Loeser C, Fliot HM, Alexander HR: Macrophage-derived tumor necrosis factor and tumor-derived leukaemia inhibitory factor and interleukin-6: possible cellular mechanisms of cancer cachexia. Ann. Surg. Oncol.3,29–35 (1996).
  Medline CASGoogle Scholar
• 17  Bing C, Bao U, Jenkins J et al.: Zinc-α2-glycoprotein, a lipid mobilising factor, is expressed in adipocytes and is up-regulated in mice with cancer cachexia. Proc. Natl Acad. Sci. USA101,2500–2505 (2004).▪▪ ZAG gene is expressed at high levels in the MAC16 tumor, liver and brown adipose tissue, and at a moderate level in heart, lung, skeletal muscle and epididymal white adipose tissue.
  Medline CASGoogle Scholar
• 18  Cariuk P, Lorite MJ, Todorov PT, Field WN, Wigmore SJ, Tisdale MJ: Induction of cachexia in mice by a product isolated from the urine of cachectic cancer patients. Br. J. Cancer76,606–613 (1997).
  Medline CASGoogle Scholar
• 19  Tisdale MJ: Mechanism of cancer cachexia. Physiol. Rev.89,381–340 (2009).
  Medline CASGoogle Scholar
• 20  Bing C, Russell S, Becket E et al.: Adipose atrophy in cancer cachexia morphologic and molecular analysis of adipose tissue in tumour-bearing mice. Br. J. Cancer95,1028–1037 (2006).
  Medline CASGoogle Scholar
• 21  Agustsson T, Ryden M, Hoffstedt J et al.: Mechanism of increased lipolysis in cancer cachexia. Cancer Res.67,5531–5537 (2007).▪▪ Lipolytic effects of catecholamines and natriuretic peptide were increased two- to three-fold in cachexia.
  Medline CASGoogle Scholar
• 22  Ryden M, Agustsson T, Laurencikiene J et al.: Lipolysis – not inflammation, cell death, or lipogenesis – is involved in adipose tissue loss in cancer cachexia. Cancer113,1695–1704 (2008).▪▪ Subcutaneous white adipose tissue does not contribute to the systemic inflammatory reaction.
  MedlineGoogle Scholar
• 23  Drott C, Persson H, Lundholm K: Cardiovascular and metabolic response to adrenaline infusion in weight-losing patients with and without cancer. Clin. Physiol.9,427–439 (1989).
  Medline CASGoogle Scholar
• 24  Shaw JH, Wolfe RR: Fatty acid and glycerol kinetics in septic patients and in patients with gastrointestinal cancer. The response to glucose infusion and parenteral feeding. Ann. Surg.205,368–376 (1987).
  Medline CASGoogle Scholar
• 25  Islam-Ali B, Khan S, Price SA, Tisdale MJ: Modulation of adipocyte G-protein expression in cancer cachexia by a lipid-mobilising factor (LMF). Br. J. Cancer85,758–763 (2001).
  Medline CASGoogle Scholar
• 26  Thompson MP, Cooper ST, Parry BR, Tuckey JA: Increased expression of the mRNA for hormone-sensitive lipase in adipose tissue of cancer patients. Biochim. Biophys. Acta1180,236–242 (1993).
  Medline CASGoogle Scholar
• 27  Laurencikiene J, Stenson BM, Nordström EA et al.: Evidence for an important role of CIDEA in human cancer cachexia. Cancer Res.68,9247–9254 (2008).▪▪ CIDEA overexpression in vitro increased the oxidation of fatty acids and decreased the oxidation of glucose and increased the expression of PDK 1 and PDK4.
  Medline CASGoogle Scholar
• 28  Lundholm K, Daneryd P, Körner U, Hyltander A, Bosaeus I: Evidence that long-term COX-treatment improves energy homeostasis and body composition in cancer patients with progressive cachexia. Int. J. Oncol.24,505–512 (2004).
  Medline CASGoogle Scholar
• 29  Virtanen KA, Lidell ME, Orava J et al.: Functional brown adipose tissue in healthy adults. N. Eng. J. Med.360,1518–1525 (2009).▪▪ First recognition of functional brown adipose tissue in humans.
  Medline CASGoogle Scholar
• 30  Shellock FG, Riedinger MS, Fishbein MC: Brown adipose tissue in cancer patients: possible cause of cancer-induced cachexia. J. Cancer Res. Clin. Oncol.111,82–85 (1986).
  Medline CASGoogle Scholar
• 31  Collins P, Bing C, McCulloch P, Williams G: Muscle UCP-3 mRNA levels are elevated in weight loss associated with gastrointestinal adenocarcinoma in humans. Br. J. Cancer86,372–375 (2002).
  Medline CASGoogle Scholar
• 32  Beutler B, Cermai A: Cachectin and tumor necrosis factor as two sides of the same biological coin. Nature320,584–588 (1986).
  Medline CASGoogle Scholar
• 33  Hirai K, Hussey HJ, Barber MD, Price SA, Tisdale MJ: Biological evaluation of a lipid-mobilizing factor isolated from the urine of cancer patients. Cancer Res.58,2359–2365 (1998).▪▪ First evidence for identity of zinc-α2-glycoprotein and lipid-mobilizing factor and selective lipid loss in vivo.
  Medline CASGoogle Scholar
• 34  Zhang HH, Halbleib M, Ahmad F, Manganiello VC, Greenberg AS: Tumor necrosis factor-α stimulates lipolysis in differentiated human adipocytes through activation of extracellular signal-related kinase and elevation of intracellular cAMP. Diabetes51,2929–2935 (2002).▪▪ Provides evidence for direct lipolysis by TNF-α.
  Medline CASGoogle Scholar
• 35  Bing C, Russell ST, Beckett EE et al.: Expression of uncoupling proteins-1, -2 and -3 mRNA is induced by an adenocarcinoma-derived lipid-mobilising factor. Br. J. Cancer86,612–618 (2002).
  Medline CASGoogle Scholar
• 36  Busquets S, Sanchis D, Alvarez B, Ricquier D, Lopez-Soriano FJ, Argiles JM: In the rat, tumor necrosis factor α administration results in an increase in both UCP2 and UCP3 mRNA in skeletal muscle: a possible mechanism for cytokine-mediated thermogenesis? FEBS Lett.440,348–350 (1998).
  Medline CASGoogle Scholar
• 37  Sanders PM, Tisdale MJ: Effect of zinc-α2-glycoprotein (ZAG) on expression of uncoupling proteins in skeletal muscle and adipose tissue. Cancer Lett.212,71–81 (2004).
  Medline CASGoogle Scholar
• 38  Russell ST, Hirai K, Tisdale MJ: Role of β3-adrenergic receptors in the action of a tumor lipid mobilising factor. Br. J. Cancer86,424–428 (2002).▪▪ Lipid-mobilizing factor was found to bind to the β3-adrenergic receptor, but the binding affinity was 100-fold less than synthetic β3-agonists.
  Medline CASGoogle Scholar
• 39  Hyltander A, Daneryd P, Sandstrom R et al.: β-adrenoreceptor activity and resting energy metabolism in weight losing cancer patients. Eur. J. Cancer36,330–334 (2000).
  Medline CASGoogle Scholar
• 40  Mracek T, Ding Q, Tzanavati T et al.: The adipokine zinc-α₂-glycoprotein is down reguated with fat mass expansion in obesity. Clin Endocrinol. DOI: 10.111/j.1365–2265.2009.0.3658.x (2010) (Epub ahead of print).
  MedlineGoogle Scholar
• 41  Rolli V, Radosavljevic M, Astier V et al.: Lipolysis is altered in MHC class I zinc-α₂-glycoprotein deficient mice. FEBS Lett.581,394–400 (2007).
  Medline CASGoogle Scholar
• 42  Bao Y, Bing C, Hunter L, Jenkins JR, Wabitsch M, Trayhurn P: zinc-α₂-glycoprotein, a lipid mobilising factor, is expressed and secreted by human (SGBS) adipocytes. FEBS Lett.579,41–47 (2005).
  Medline CASGoogle Scholar
• 43  Khal J, Hine AV, Fearon KCH, Dejong CHC, Tisdale MJ: Increased expression of proteasome subunits in skeletal muscle of cancer patients with weight loss. Int. J. Biochem. Cell Biol.37,2196–2206 (2005).
  Medline CASGoogle Scholar
• 44  Eley HL, Skipworth RJE, Deans DAC, Fearon KCH, Tisdale MJ: Increased expression of phosphorylated forms of RNA-dependent protein kinase and eukaryotic initiation factor 2α may signal skeletal muscle atrophy in weight-losing cancer patients. Br. J. Cancer98,442–449 (2008).
  Google Scholar
• 45  Emery PW, Edwards RHT, Rennie MJ, Souhami RL, Halliday D: Protein synthesis in muscle measured in vivo in cachectic patients with cancer. Br. Med. J.289,584–588 (1984).
  Medline CASGoogle Scholar
• 46  Eley HL, Tisdale MJ: Skeletal muscle atrophy, a link between depression of protein synthesis and increase in degradation. J. Biol. Chem.282,7087–7097 (2007).▪▪ Phosphorylation of PKR has been shown to be central to the depression of protein synthesis and increase in protein degradation in skeletal muscle.
  Medline CASGoogle Scholar
• 47  Llovera M, Lopez-Soriano FJ, Argiles JM: Effects of tumor necrosis factor-α on muscle protein turnover in female Wistar rats. J. Natl Cancer Inst.85,1334–1339 (1993).
  Medline CASGoogle Scholar
• 48  Tsujinaka T, Fujita J, Ebisui C et al.: Interleukin 6 receptor antibody inhibits muscle atrophy and modulates proteolytic systems in interleukin 6 transgenic mice. J. Clin. Invest.97,244–249 (1996).
  Medline CASGoogle Scholar
• 49  Llovera M, Carbo N, Lopez-Soriano FJ et al.: Different cytokines modulate ubiquitin gene expression in rat skeletal muscle. Cancer Lett.13,83–87 (1998).▪▪ In vivo study showing that TNF-α and IFN-γ increase protein degradation in skeletal muscle through the ubiquitin–proteasome pathway, while IL-6 and leukemia-inhibitory factor do not.
  Google Scholar
• 50  Batgalvis KA, Berger FG, Pena MMD, Davis JM, Muga SJ, Carson JA: Interleukin-6 and cachexia in Apc^Min/+mice. Am. J. Physiol. Regul. Integr. Comp. Physiol.294,R393–R401 (2008).
  MedlineGoogle Scholar
• 51  Garcia Martinez C, Llovera M, Agell N et al.: Ubiquitin gene expression in skeletal muscle is increased during sepsis. Involvement of TNF-α but not IL-1. Biochem. Biophys. Res. Commun.217,839–844 (1995).
  Medline CASGoogle Scholar
• 52  Lorite MJ, Smith HJ, Arnold JA, Morris A, Thompson MG, Tisdale MJ: Activation of ATP-ubiquitin-dependent proteolysis in skeletal muscle in vivo and murine myotubes in vitro by a proteolysis-inducing factor (PIF). Br. J. Cancer85,297–302 (2001).▪▪ Provides evidence for direct activation of the ubiquitin–proteasome pathway by proteolysis-inducing factor (PIF).
  Medline CASGoogle Scholar
• 53  Li Y-P, Chen Y, John J et al.: TNF-α acts via p38 MAPK to stimulate expression of the ubiquitin ligase atrogin 1/MAFbx in skeletal muscle. FASEB J.19,362–370 (2005).
  Medline CASGoogle Scholar
• 54  Li Y-P, Schwartz RJ, Waddell ID, Holloway BR, Reid MB: Skeletal muscle myocytes undergo protein loss and reactive oxygen-mediated NF-κB activation in response to tumor necrosis factor α. FASEB J.12,871–880 (1998).
  Medline CASGoogle Scholar
• 55  Russell ST, Eley H, Tisdale MJ: Role of reactive oxygen species in protein degradation in murine myotubes induced by proteolysis-inducing factor and angiotensin II. Cell. Sig.19,1797–1806 (2007).
  Medline CASGoogle Scholar
• 56  Eley HL, Russell ST, Tisdale MJ: Attenuation of depression of muscle protein synthesis induced by lipopolysaccharide, tumor necrosis factor, and angiotensin II by β-hydroxy-β-methylbutyrate. Am. J. Physiol. Endocrinol. Metab.295,E1409–E1416 (2008).▪▪ Provides evidence that TNF-α, lipopolysaccharide and angiotensin II depress protein synthesis in muscle by the same mechanism as PIF.
  Medline CASGoogle Scholar
• 57  Schwarzkopf M, Coletti D, Sassoon D, Marazzi G: Muscle cachexia is regulated by a p53-PW1/Peg3-dependent pathway. Genes Develop.20,3440–3452 (2006).
  Medline CASGoogle Scholar
• 58  Gutteridge DC, Mayo MW, Madrid LV, Wang CY, Baldwin AS Jr: NF-κB-induced loss of MyoD messenger RNA: possible role in muscle decay and cachexia. Science289,2363–2366 (2000).
  MedlineGoogle Scholar
• 59  Ling PR, Schwartz JH, Bistrian BR: Mechanisms of host wasting induced by administration of cytokines in rats. Am. J. Physiol. Endocrinol. Metab.272,E333–E339 (1997).▪▪ Tissue wasting caused by cytokines includes a metabolic component, which is different from and additive to that caused by anorexia.
  CASGoogle Scholar
• 60  Lorite MJ, Thompson MG, Drake JL, Carling G, Tisdale MJ: Mechanism of muscle protein degradation induced by a cancer cachectic factor. Br. J. Cancer78,850–856 (1998).
  Medline CASGoogle Scholar
• 61  Lorite MJ, Cariuk P, Tisdale MJ: Induction of muscle protein degradation by a tumour factor. Br. J. Cancer76,1035–1040 (1997).
  Medline CASGoogle Scholar
• 62  Llovera M, Lopez-Soriano FJ, Argiles JM: Effects of tumor necrosis factor-α on muscle protein-turnover in female Wistar rats. J. Natl Cancer Inst.85,1334–1339 (1993).
  Medline CASGoogle Scholar
• 63  Norton JA, Morley JF, Green MV et al.: Parabiotic transfer of cancer anorexia/cachexia in male rats. Cancer Res.45,5547–5552 (1985).
  Medline CASGoogle Scholar
• 64  Todorov P, Cariuk P, McDevitt T, Coles B, Fearon K, Tisdale M: Characterization of a cancer cachectic factor. Nature379,739–742 (1996).
  Medline CASGoogle Scholar
• 65  Todorov PT, Field WN, Tisdale MJ: Role of a proteolysis-inducing factor (PIF) in cachexia induced by a human melanoma (G361). Br. J. Cancer80,1734–1737 (1990).
  Google Scholar
• 66  Monitto CL, Dong S-M, Jen J, Sidransky D: Characterization of a human homologue of proteolysis-inducing factor and its role in cancer cachexia. Clin. Cancer Res.10,5862–5869 (2004).
  Medline CASGoogle Scholar
• 67  Todorov PT, Deacon M, Tisdale MJ: Structural analysis of a tumor-produced sulfated glycoprotein capable of initiating muscle protein degradation. J. Biol. Chem.272,12279–12288 (1997).▪▪ Demonstrates that both the biological and immunological effects of PIF are mediated through the oligosaccharide chains, and that 85% of PIF is carbohydrate.
  Medline CASGoogle Scholar
• 68  Schittek B, Hipfel R, Sauer B et al.: Dermicidin: a novel human antibiotic peptide secreted by sweat glands. Immunol. Nat.2,1133–1137 (2001).
  Medline CASGoogle Scholar
• 69  Wang Z, Corey E, Hass GM et al.: Expression of the human cachexia-associated protein (HCAP) in prostate cancer and in a prostate cancer animal model of cachexia. Int. J. Cancer105,123–129 (2003).
  Medline CASGoogle Scholar
• 70  Wigmore SJ, Todorov PT, Barber MD, Ross JA, Tisdale MJ, Fearon KCH: Characteristics of patients with pancreatic cancer expressing a novel cancer cachectic factor. Br. J. Surg.87,53–58 (2000).
  Medline CASGoogle Scholar
• 71  Cabal-Manzano R, Bhargava P, Torres-Duarte A, Marshall J, Bhargava P, Wainer IW: Proteolysis-inducing factor is expressed in tumours of patients with gastrointestinal cancers and correlates with weight loss. Br. J. Cancer84,1599–1601 (2001).▪▪ Provides evidence that tumors are the source of PIF in humans.
  Medline CASGoogle Scholar
• 72  Williams ML, Torres-Duarte A, Brant LJ, Bhargava P, Marshall J, Wainer IW: The relationship between a urinary cachectic factor and weight loss in advanced cancer patients. Cancer Invest.22,866–870 (2004).
  Medline CASGoogle Scholar
• 73  Wieland BM, Stewart GD, Skipworth RJE et al.: Is there a human homologue to the murine proteolysis-inducing factor? Clin. Cancer Res.13,4984–4992 (2007).
  Medline CASGoogle Scholar
• 74  Kamoshida S, Watanabe, Suzuki M et al.: Expression of cancer cachexia-related factors in human cancer xenografts: an immunohistochemical analysis. Biomed. Res.27,275–281 (2006).
  Medline CASGoogle Scholar
• 75  Karayiannakis AJ, Syrigos KN, Polychronidis A et al.: Serum levels of tumor necrosis factor-α and nutritional status in pancreatic cancer patients. Anticancer Res.21,1355–1358 (2001).
  Medline CASGoogle Scholar
• 76  Bossola M, Muscaritoli M, Bellantone R et al.: Serum tumor necrosis factor-α levels in cancer patients correlate with weight loss. Eur. J. Clin. Invest.30,1107–1112 (2000).
  Medline CASGoogle Scholar
• 77  Ebrahimi B, Tuker SL, Li D et al.: Cytokines in pancreatic carcinoma. Cancer101,2727–2736 (2004).
  Medline CASGoogle Scholar
• 78  Socher SH, Martinez D, Craig JB, Kuhn JG, Oliff A: Tumor necrosis factor not detectable in patients with clinical cancer cachexia. J. Natl Cancer Inst.50,595–598 (1998).
  Google Scholar
• 79  Maltoni M, Fabbri L, Nanni O et al.: Serum levels of tumour necrosis factor and other cytokines do not correlate with weight loss and anorexia in cancer patients. Support. Care Cancer5,130–135 (1997).
  Medline CASGoogle Scholar
• 80  Adami F, Guarini A, Pini M et al.: Serum levels of tumour necrosis factor-α in patients with B-cell chronic lymphocytic leukaemia. Eur. J. Cancer30A,1259–1263 (1994).
  Medline CASGoogle Scholar
• 81  McKeowa DJ, Brown DFJ, Kelly A et al.: The relationship between circulating concentrations of C-reactive protein, inflammatory cytokines and cytokine receptors in patients with nonsmall cell lung cancer. Br. J. Cancer91,1993–1995 (2004).
  MedlineGoogle Scholar
• 82  Costelli P, Bossola M, Muscaritoli M et al.: Anticytokine treatment prevents the increase in the activity of the ATP-ubiquitin-and Ca²⁺-dependent proteolytic systems in the muscle of tumour-bearing rats. Cytokine19,1–5 (2002).
  Medline CASGoogle Scholar
• 83  Goldberg RM, Loprinzi CL, Malliard JA et al.: Pentoxyifylline for treatment of cancer anorexia and cachexia? A randomised, double-blind, placebo-controlled trial. J. Clin. Oncol.13,2856–2859 (1995).
  Medline CASGoogle Scholar
• 84  Costelli P, Carbo N, Tessitore L et al.: Tumor necrosis factor-α mediates changes in tissue protein turnover in a rat cancer cachexia model. J. Clin. Invest.92,2783–2789 (1993).
  Medline CASGoogle Scholar
• 85  Widenmann B, Malfertheiner P, Freiss H et al.: A multicenter Phase II study of infliximab plus gemcitabine in pancreatic cancer cachexia. J. Support. Oncol.6,18–25 (2008).▪▪ Antibody to TNF-α failed to attenuate cachexia in cancer patients.
  MedlineGoogle Scholar
• 86  Wyke SM, Russell ST, Tisdale MJ: Induction of proteasome expression in skeletal muscle is attenuated by inhibitors of NF-κB activation. Br. J. Cancer91,1742–1750 (2004).
  Medline CASGoogle Scholar
• 87  Eley HL, Russell ST, Tisdale MJ: Attenuation of muscle atrophy in a murine model of cachexia by inhibition of the dsRNA-dependent protein kinase. Br. J. Cancer96,1216–1222 (2007).
  Medline CASGoogle Scholar
• 88  Eley HL, Russell ST, Tisdale MJ: Effect of branched-chain amino acids on muscle atrophy in cancer cachexia. Biochem. J.407,113–120 (2007).
  Medline CASGoogle Scholar
• 89  Russell ST, Siren PMA, Siren MJ, Tisdale MJ: Attenuation of skeletal muscle atrophy in cancer cachexia by D-myo-inositol 1, 2 6-triphosphate. Cancer Chemother. Pharmacol.64,517–527 (2009).▪▪ Provides evidence for a role of divalent metal ions in the cachectic process.
  Medline CASGoogle Scholar
• 90  Smith HJ, Mukerji P, Tisdale MJ: Attenuation of proteasome-induced proteolysis in skeletal muscle by β-hydroxy-β-methylbutyrate in cancer-induced muscle loss. Cancer Res.65,277–283 (2005).
  Medline CASGoogle Scholar
• 91  Beck SA, Smith KL, Tisdale MJ: Anticachectic and antitumour effect of eicosapentaenoic acid and its effect on protein turnover. Cancer Res.51,6089–6093 (1991).
  Medline CASGoogle Scholar
• 92  Todorov PT, Wyke SM, Tisdale MJ: Identification and characterisation of a membrance receptor for proteolysis-inducing factor in skeletal muscle. Cancer Res.67,11419–11427 (2007).
  Medline CASGoogle Scholar
• 93  Wigmore SJ, Barber MD, Ross JA, Tisdale MJ, Fearon KCH: Effect of oral eicosapentaenoic acid on weight loss in patients with pancreatic cancer. Nutr. Cancer36,177–184 (2000).
  Medline CASGoogle Scholar
• 94  Fearon KCH, van Meyenfeldt MF, Moses AGW et al.: Effect of a protein and energy dense n-3 fatty acid enriched oral supplement on loss of weight and lean tissue in cancer cachexia: a randomised double blind trial. Gut52,1479–1486 (2003).
  Medline CASGoogle Scholar
• 95  May PE, Barber A, D’Olimpio JT, Hourihane A, Abumrad NN: Reversal of cancer-related wasting using oral supplementation with a combination of β-hydroxy-β-methylbutyrate, arginine, and glutamine. Am. J. Surg.183,471–479 (2002).
  Medline CASGoogle Scholar
• 96  Deans DAC, Tan BHL, Ross JA et al.: Cancer cachexia is associated with the IL10-1082 gene promoter polymorphism in patients with gastroesophageal malignancy. Am. J. Clin. Nutr.89,1164–1172 (2009).▪▪ Suggests that some patients may be more susceptible to the development of cachexia due to polymorphisms of genes for some cytokines.
  Medline CASGoogle Scholar
• 97  Lainscak M, Podbregar M, Anker SD: How does cachexia influence survival in cancer, heart failure and other chronic diseases? Curr. Opin. Support. Pall. Care1,299–305 (2007).
  MedlineGoogle Scholar